Business Wire

HTEC and Xsolis’ Strategic Partnership to Tackle Inefficiencies in Healthcare Decision-Making with AI

2.6.2026 14:38:00 CEST | Business Wire | Press Release

Share

HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602462348/en/

HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers.

Across healthcare systems, determining whether a treatment is medically necessary, what level of care a patient requires, and whether that care will be approved remains a slow, manual, and often inconsistent process. Known as utilization management, this function sits at the heart of healthcare operations—but is still heavily reliant on fragmented data, manual reviews, and subjective judgment. The result is delays in care, administrative burden, rising costs, and friction between providers and payers.

Xsolis addresses these challenges through its Dragonfly® platform, which uses real-time patient data, machine learning, and predictive analytics to bring greater objectivity, speed, and transparency to decision-making. By continuously analysing patient condition and care requirements, the platform helps healthcare organizations align faster on medical and care decisions while reducing operational inefficiencies, administrative waste, and friction between providers and payers.

Through this partnership, HTEC will play a central role in advancing the Dragonfly platform—bringing deep expertise in AI-enabled product engineering and software development lifecycle (SDLC), as well as scalable cloud-based systems and AI tooling.

HTEC will support the continued evolution of the platform’s predictive capabilities across key healthcare workflows, including utilization management, discharge readiness prediction, appeals and denials management, and operational analytics for providers and payer organizations. The collaboration will focus on embedding agentic AI to improve workflow automation, accelerate data-driven decision-making, and enhance operational intelligence, while modernizing the underlying engineering environment to speed innovation and ensure compliance with strict healthcare regulations.

A key differentiator of the partnership is HTEC’s AI-powered approach to software delivery. By embedding AI across the end-to-end SDLC—from translating product requirements and generating specifications to accelerating development, QA, code review, and delivery tracking—HTEC helps organizations improve engineering efficiency, increase release velocity, and bring new capabilities to market faster. Working closely with Xsolis, HTEC will help identify and implement the right AI-enabled engineering practices and tooling to streamline product development while maintaining the reliability, transparency, and compliance required in healthcare technology environments.

“Xsolis is addressing some of healthcare’s most operationally complex challenges through AI-driven clinical and operational decision support,” said Lawrence Whittle, Chief Strategy Officer at HTEC. “We’re excited to bring our healthcare engineering expertise and AI-first delivery approach to support the continued evolution of the Dragonfly platform. Together, we aim to help healthcare organizations operate more efficiently while enabling better experiences for providers, payers, and patients.”

“HTEC stood out because of its strong engineering culture, healthcare domain expertise, and practical approach to applying AI across both product innovation and software delivery,” said Zach Evans, CTO at Xsolis. “As we continue to expand the Dragonfly platform, we see HTEC as a strategic partner that can help accelerate innovation while maintaining the reliability, compliance, and operational excellence our customers expect.”

The collaboration reflects a shared commitment to solving one of healthcare’s most pressing challenges: how to deliver faster, more aligned care decisions at scale while reducing cost and complexity. By combining Xsolis’ AI-driven decision intelligence with HTEC’s ability to engineer, scale, and operationalise advanced AI systems, the partnership is positioned to deliver measurable impact across healthcare organizations.

About Xsolis

Xsolis is an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Dragonfly®, its AI-driven proprietary platform, is the first and only solution to use real-time predictive analytics to continuously assign an objective medical necessity score and assess the anticipated level of care for every patient, enabling more efficiency across the healthcare system. Xsolis is headquartered in Franklin, Tennessee. For more information, visit www.xsolis.com.

About HTEC

HTEC Group Inc. is a global AI-first provider of complex software and hardware embedded design and engineering services, specializing in Advanced Technologies, Financial Services, MedTech, Automotive, Telco, and Enterprise Software & Platforms. HTEC has a proven track record of helping Fortune 500 and hyper-growth companies solve complex engineering challenges, drive efficiency, reduce risks, and accelerate time to market. HTEC prides itself on attracting top talent and has strategically chosen the locations of its 20+ excellence centers to enable this.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260602462348/en/

Contacts

Media contact: media@htecgroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release

A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye